Drug profile · INN
insulin aspart recombinant
NOVOLOG PENFILL
insulin aspart recombinant (NOVOLOG PENFILL) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin aspart recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
insulin aspart recombinant (NOVOLOG PENFILL) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin aspart recombinant?
insulin aspart recombinant (NOVOLOG PENFILL) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin aspart recombinant?
NOVOLOG PENFILL is a marketed brand name for insulin aspart recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin aspart recombinant?
insulin aspart recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.